Condition

Respiratory Syncytial Virus (RSV) clinical trials and research

• 18Clinical trials
• 1NIH research projects
• 1New in 30 days
• 14Countries

Newest Respiratory Syncytial Virus (RSV) clinical trials

All recruiting trials (18)

• RSV vaccine safety and immune response in lung transplant patients vs. healthy adults

  This study tests how well the RSV vaccine works and how safe it is in people who have had a lung transplant compared with healthy adults.

  Recruiting Phase 4 Seoul National University Hospital · Seoul, Jongno-Gu · NCT07895394

• RSV vaccine in children at high risk to see if it is safe and makes a strong immune response

  This study tests whether the RSVpreF vaccine is safe and helps the immune system in children aged 5 to under 18 who are at high risk for RSV illness, including those who are immunocompromised.

  Recruiting at 11 sites Phase 3 Pfizer · Durham, North Carolina and 19 other locations · NCT07839871

• Revaccination with RSVpreF in Immunocompromised Adults

  This study tests whether giving an RSVpreF vaccine shot again at about 1, 2, and 3 years is safe and can still provoke an immune response in adults who are immunocompromised.

  Recruiting at 13 sites Phase 3 Pfizer · Los Angeles, California and 16 other locations · NCT07768345

• Vaccine candidates for RSV and hMPV in older adults

  This study tests whether mRNA-1365 and related vaccine profiles are safe and able to trigger an immune response in healthy older adults.

  Recruiting at 2 sites Phase 1 ModernaTX, Inc. · Québec, Quebec and 9 other locations · NCT07764237

• YKYY025 Injection safety and immune response test in adults

  This phase 1 study tests whether YKYY025 is safe and prompts an immune response in healthy adults.

  Recruiting Phase 1 Youcare Pharmaceutical Group Co., Ltd. · Anning, Yunnan · NCT07694557

• RSVpreF vaccine in adults: safety and immune response in India

  A Phase 3 test of the RSVpreF vaccine vs placebo in adults 18 and older living in India to see if it is safe and produces an immune response.

  Recruiting at 13 sites Phase 3 Pfizer · Visakhapatnam, Andhra Pradesh and 12 other locations · NCT07653100

• Passive RSV antibody to protect Aboriginal and Torres Strait Islander infants

  This trial tests whether giving a single shot of the RSV antibody nirsevimab to Aboriginal and Torres Strait Islander infants around 6 months old can reduce RSV infections in the first year of life.

  Recruiting Phase 4 Menzies School of Health Research · Darwin, Northern Territory · NCT07578298

• Different vaccine formulations for RSV or H5 flu in adults 18–49

  This trial will try several vaccine formulations that produce either the RSV antigen or the H5 flu antigen in healthy adults 18 to 49 to see if they are safe and trigger immune responses.

  Recruiting at 6 sites Phase 1 Sanofi · Griffith, Queensland and 5 other locations · NCT07516418

• Zelicapavir for RSV infection in young children

  This study tests whether Zelicapavir can help treat RSV infection in children aged 28 days to 36 months who are showing symptoms.

  Recruiting at 8 sites Phase 2 Enanta Pharmaceuticals, Inc · Bangkok and 7 other locations · NCT07482657

• Maternal RSV Vaccine Before Birth and Infant RSV-Related Illness in Brazil

  This study tests whether maternal RSVpreF vaccination during pregnancy reduces medically attended RSV-related illnesses in infants in Brazil.

  Recruiting at 8 sites Inova Medical · Cascavel, Paraná and 7 other locations · NCT07445763

• Community spread of multiple infectious diseases in Cambodia from a One Health perspective

  This project will test how common and connected dengue, chikungunya, Zika, Japanese encephalitis, and West Nile infections are among people, animals, and the environment across Cambodia.

  Recruiting Institut Pasteur du Cambodge · Phnom Penh, Phnom Penh · NCT07358910

• Recombinant RSV (CHO cell) vaccine to prevent lower respiratory disease in adults 60+

  This trial will test whether a single dose of a recombinant RSV (CHO cell) vaccine can prevent RSV-related lower respiratory tract disease and is safe in adults aged 60 and older.

  Recruiting at 5 sites Phase 3 MAXVAX Biotechnology Limited Liability Company · Guangzhou, Guangdong and 7 other locations · NCT07272434

• SIBP-A16 injections in healthy adults to find safe doses and routes

  This trial will test different doses and ways of giving SIBP-A16 to see if they are safe and how the body handles the drug in healthy adults.

  Recruiting Early Phase 1 Shanghai Institute Of Biological Products · Wuhan · NCT07106918

• Arexvy (RSVPreF3) vaccine for people with weakened immune systems

  This trial will test whether one or two doses of the Arexvy RSV vaccine help people with weakened immune systems make protective immune responses and will track side effects.

  Recruiting Phase 2 Johns Hopkins University · Baltimore, Maryland · NCT07050732

• Aerosolized Peginterferon α-2b for treating RSV pneumonia in young children

  This study is testing if a new inhaled treatment can help young children with RSV pneumonia feel better.

  Recruiting at 2 sites West China Second University Hospital · Chengdu, Sichuan and 1 other locations · NCT06881056

• Five-day remdesivir treatment for hospitalized infants with RSV

  This trial tests a five-day intravenous course of remdesivir in hospitalized children under two with confirmed RSV to see if it is safe and lowers the amount of virus.

  Recruiting at 6 sites Phase 2 PENTA Foundation · Bangkok and 7 other locations · NCT06873633

• Registry for monitoring RSV vaccine effects during pregnancy

  This study is tracking the health of pregnant people who received the RSV vaccine in late pregnancy to see if it affects their pregnancy outcomes and their babies.

  Recruiting CorEvitas · Wilmington, North Carolina · NCT06521944

• Stopping antibiotics for viral respiratory infections

  This study is testing if hospitalized adults with viral respiratory infections can safely stop taking antibiotics without affecting their recovery compared to those who keep taking them.

  Recruiting at 8 sites Phase 4 University Hospital, Akershus · Bergen and 11 other locations · NCT05045612

NIH-funded research (1)

Early-stage science funded by the US National Institutes of Health. Most of these projects don't enroll patients, but they show what is being worked on.

• A new vaccine to protect children from respiratory viruses.

  This study is testing a new nose spray vaccine that could help protect young children from serious respiratory infections caused by RSV and HMPV, making it easier for them to stay healthy and breathe better.

  NIH research Cyanvac, LLC · Athens, United States · NIH-10920481

Related topics

Quick answers

How many Respiratory Syncytial Virus (RSV) clinical trials are recruiting right now?

18, as of November 12, 2026. 1 of them was first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 14 countries. The most sites are in China (4 trials), United States (4 trials), Thailand (2 trials), Australia (2 trials), Brazil (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 3: 4, Phase 2: 3, Phase 1: 3, Phase 4: 3. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →